Amgen showcases a legacy of science, innovation and collaboration in Cambridge

AmgenWhen Amgen (NASDAQ:AMGN) purchased a vacant parcel of land in the heart of Kendall Square in Cambridge, Mass. 25 years ago, the area was far from the thriving biotechnology hub it has since become. In 2001, Amgen, a biotechnology pioneer, completed construction of an eight-story, 297,000-square-foot facility on the site. Now one of the world's leading independent biotechnology companies, Amgen has expanded its presence in Cambridge and today hosted members of the Massachusetts life sciences community and government officials at its newly renovated research and process development facility.

The event commemorated the completion of a renovation featuring next-generation laboratories and offices, a process development scale-up laboratory visible from the exterior and an interactive lobby highlighting Amgen's science and patient stories. Amgen has invested approximately $100 million in the Cambridge facility since 2015, and more than 400 staff are based at the site.

"Amgen's state-of-the-art facility here in Cambridge exemplifies what it means to be at the cutting edge of biomedical research," said Robert A. Bradway, chairman and chief executive officer at Amgen. "Many of the ingredients you need to foster innovation are right here - talented people, the latest technology, and an environment conducive to advancing science. We chose Cambridge as one of our core research hubs because it is an environment with a thriving life sciences ecosystem that encourages innovation."

The site accommodates research scientists with expertise in therapeutic discovery, specifically within medicinal chemistry, molecular engineering and discovery attribute sciences. Process development scientists and engineers support product commercialization and the advancement of manufacturing innovation.

"Massachusetts is a global leader in technology, innovation, research and development because of the early investment and continued impact of companies like Amgen," said Governor Charles Baker. "We welcome Amgen's growth in Cambridge and the future healthcare advancements for patients around the world that will come of their updated state-of-the-art facility."

Amgen's neuroscience research group is based at the site, with efforts focused on migraine, analgesia, Alzheimer's disease, and other chronic neurodegenerative diseases. Scientists within the neuroscience therapeutic area in Cambridge support Amgen's migraine prevention clinical development program by investigating the cellular mechanism of action of the Calcitonin Gene-Related Peptide (CGRP) receptor, furthering the Company's understanding in this area.

"Amgen's ongoing commitment to Cambridge further strengthens Massachusetts' position as a global biosciences beacon," said Senator Edward Markey. "From helping to cure Alzheimer's to preventing migraine, the scientists and staff at Amgen will continue to discover and develop breakthroughs and medicines that will drive the life sciences for generations to come."

The new process development scale-up laboratory provides a dedicated space for staff to test cutting-edge technologies focused on next-generation biomanufacturing. The company embarked on developing an open environment setting, designed for staff to share and communicate ideas easier, to enable more efficient decision-making and to foster greater collaboration amongst staff and the surrounding life sciences community. The lobby showcases interactive, visual elements to describe Amgen's biology-first approach to understanding disease, and patient and research videos highlighting Amgen's focus in cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation.

Since 2014, Amgen has entered into collaborations with LabCentral, Boston Children's Hospital, Harvard Department of Molecular and Cellular Biology, as well as others.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

A great place to do great things: Developing game-…

Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal Science today recognized...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Scientists find where HIV 'hides' to evade detecti…

In a decades-long game of hide and seek, scientists from Sydney's Westmead Institute for Medical Research have confirmed for the very first time the specific immune memor...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]